TickerTalks
Browse all tickers →
TickerTalks›$YDES
YDYDES

YD Bio Limited Ordinary Shares

$YDES·$154M·Biotechnology·Healthcare
$4.52-3.6%YTD-81.0%1Y-50.6%
Mentions · last 7 days
2026-08-17: 0 posts2026-08-18: 9 posts2026-08-19: 5 posts2026-08-20: 2 posts2026-08-21: 3 posts2026-08-22: 0 posts2026-08-23: 1 posts20+19%
Price updated 1m ago·X counts updated 21h ago
YDYDES
$YDESYD Bio Limited Ordinary Shares
$4.52-3.62%20 posts+19%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $YDES, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellStalledAI verdict · as of 2026-08-23

The move has stalled — likely just drifts unless something new shows up.

YD Bio down 81% YTD on DNA-methylation cancer-detection expansion — no revenue, no earnings visibility, story-mode.

YD Bio is a small-cap biotech expanding DNA-methylation-based early-cancer-detection operations, with a US laboratory footprint now covering 46 states and cross-border pilots with Numia Health in Canada. The 81% YTD drawdown puts this squarely in busted-story territory.

  • There are no financials to underwrite. Reported quarterly revenue is zero going back at least four quarters (Q2 2025, Q1 2025, Q4 2024, Q3 2024), gross margin is null, operating margin is null, and EPS runs $0.65 to $0.98 loss per quarter. TTM P/S reads as zero. No forward analyst estimates, no next-earnings date on the calendar. That is the profile of a company running on cash-burn against a commercial-launch narrative, not on revenue.
  • Market cap is $153M against zero recurring revenue — the multiple is 100% story. Debt/equity is essentially zero, so there is no leverage backstop; the cash runway (not in the bundle) is the load-bearing variable, and that has to be validated against filings before conviction is possible.
  • The operational cadence is real if unproven: the July 2 expansion-to-46-states press release, the July 23 BIO Asia-Taiwan 2026 exhibition with EG BioMed on ophthalmology and oncology diagnostics, and the July 28 Numia Health cross-border pilot suggest management is executing a commercialization playbook. Whether that converts to booked revenue is entirely open.
  • The August 16 head-to-head vs Arbutus piece is thin-signal coverage — algorithmic comparison content, not a substantive analyst call. Structural tape: tiny float bucket, 30-day volume 0.79x average, price at 13th percentile of the 52-week range. Nobody is chasing this yet, and nobody is capitulating either — a stalled hold.
  • Watch for the first quarter with reported revenue or any capital raise disclosure.
Differs from X sentimentNo X sentiment bundle was supplied for this ticker, so there is no crowd read to align against — verdict is anchored on the 81% YTD move, the zero-revenue quarterly base, and the DNA-methylation commercial-launch narrative in the news bundle.

What to watch: Any capital raise or dilution filing, the first quarter with reported diagnostic revenue, additional payer or hospital-system contracts, and clinical-utility data supporting the methylation platform.

Read the AI verdict + X sentiment for $YDES

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Taiwan clinical-stage biotech developing liquid biopsy cancer diagnostics and exosome-based therapeutics for diseases with unmet medical needs.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $YDES.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $YDES

Neutral — Taiwan clinical-stage biotech developing liquid biopsy cancer diagnostics and exosome-based therapeutics for diseases with unmet medical needs; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-6.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
52.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY25$0———$-0.65$-298K
Q1 FY25$0———$-0.98$-490K
Q4 FY24$0———$0.10$-366K
Q3 FY24$0———$0.54$-22K

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+80.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-33.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 1.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.125-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (4 awards · 4 exempts) in window

See when $YDES insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3/ANew insider — initial holdingsApr 203/A
3New insider — initial holdingsApr 23
3New insider — initial holdingsApr 23
3New insider — initial holdingsMar 303
3New insider — initial holdingsMar 273
3New insider — initial holdingsMar 263
3New insider — initial holdingsMar 183
+ 6 other (3 6-Ks · 1 EFFECT · 1 POS AM · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)defenseworld.net·9d agoYD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canadaglobenewswire.com·27d agoYD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Servicesglobenewswire.com·32d agoYD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operationsglobenewswire.com·53d agoYD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operationsglobenewswire.com·53d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$CAPR$IOVA$NWBO$SLS$ABCL
Voices on X · last 7 days

No standout posts about $YDES on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport